Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.84 |
| ▸ | JAK2 | O60674 | 1/20 | 0.84 |
| ▸ | ULK1 | O75385 | 1/20 | 0.84 |
| ▸ | ERN1 | O75460 | 1/20 | 0.84 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | KRAS | P01116 | 1/20 | 0.84 |
| ▸ | RAF1 | P04049 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
| ▸ | CDK1 | P06493 | 1/20 | 0.84 |
| ▸ | YES1 | P07947 | 1/20 | 0.84 |
| ▸ | LYN | P07948 | 1/20 | 0.84 |
| ▸ | MET | P08581 | 1/20 | 0.84 |
| ▸ | HCK | P08631 | 1/20 | 0.84 |
| ▸ | FGR | P09769 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127717 | 0.93 | BRAF (0.83) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 0.92 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29350038 | 0.92 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29353365 | 0.92 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193062 | 0.92 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.91 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL1127269 | 0.89 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29352214 | 0.89 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733912 | 0.89 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL1127301 | 0.88 | BRAF (0.83) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196879-A1 | Pharmaceutical Combination of MEK Inhibitor and B-RAF Inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196879-A1 | Pharmaceutical Combination of MEK Inhibitor and B-RAF Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885NR1I2 3168/4885PLK4 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.